Frykman, H, Kumar, P. Laboratory Testing of Myasthenia Gravis: New Treatments Drive Change, The Journal of Applied Laboratory Medicine, , jfaa199, https://doi.org/10.1093/jalm/jfaa199
Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250‐e1255. doi:10.1212/WNL.0000000000007096
Yeh EA, Nakashima I. Live-cell based assays are the gold standard for anti-MOG-Ab testing. Neurology. 2019;92(11):501‐502. doi:10.1212/WNL.0000000000007077
Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. Published 2018 May 3. doi:10.1186/s12974-018-1144-2
Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87(9):1005‐1015. doi:10.1136/jnnp-2015-312601
Rodríguez Cruz PM, Al-Hajjar M, Huda S, et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol. 2015;72(6):642‐649. doi:10.1001/jamaneurol.2015.0203
Chang T, Leite MI, Senanayake S, et al. Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. J Neurol Sci. 2014;343(1-2):82-87. doi:10.1016/j.jns.2014.05.037
Fronda A, Gibbs E, Aziz T, Oger J (2014). Detection Of Anti-Natalizumab Antibodies In Treated Multiple Sclerosis Patients Using a Biacore™ Platform (P4.139). Neurology Apr 2014, 82 (10 Supplement) P4.139;
Fronda A, Kuan A, Fritzler M, Fujihara K, Takahashi T. (2012). NMO-IgG as Measured in Multiple Facilities in Optic Neuritis (ON), Transverse Myelitis (TM) and Combinations Thereof (P02.130). Neurology. 78. P02.130-P02.130. 10.1212/WNL.78.1_MeetingAbstracts.P02.130.